Organon Stock Surges After Reports of $13 Billion Buyout Bid by Sun Pharma 
$16B Michigan Data Center Project Boosts U.S. AI Infrastructure Expansion 
Florida Launches Criminal Probe Into OpenAI Over FSU Shooting Incident 
DeepSeek V4 Launch Signals China’s Growing AI Independence with Huawei Chips 
Tesla Earnings Beat Expectations as EV Growth Holds Amid Robotics and AI Shift 
Mercedes-Benz Faces Rising Competition in China but Rejects Price War Strategy 
PLS Reports Record Lithium Output as EV Demand Fuels Market Growth 
DeepSeek Launches V4 AI Models with Enhanced Reasoning and 1M Token Context Window 
Nvidia Pushes 800V Data Center Power Systems to Boost Efficiency and Cut Costs 
Judge Dismisses Elon Musk’s Fraud Claims Against OpenAI, Trial to Proceed on Remaining Allegations 
Strait of Hormuz Shipping Crisis Deepens as Traffic Plunges Amid Iran-U.S. Tensions 
Brazil Pension Fund Crackdown After Banco Master Collapse Raises Investment Concerns 
Hyundai Plans 20 New Models in China to Boost EV Strategy and Market Share 
Intel Stock Surges as AI Chip Demand Drives Strong Q2 Forecast 
Meta Expands AI Training With Employee Activity Tracking Tools 
Brazil Blocks Prediction Market Platforms, Tightens Derivatives Trading Rules 
WALTHAM, Mass., May 15, 2017 -- Syndax Pharmaceuticals, Inc. (Nasdaq:SNDX), a clinical stage biopharmaceutical company developing entinostat and SNDX-6352 in multiple cancer indications, today announced that Chief Executive Officer Briggs W. Morrison, M.D., will present at the 2017 UBS Global Healthcare Conference on May 22, 2017 at 11:30 am EDT at the Grand Hyatt New York.
A live webcast of the Company's presentation can be accessed from the Investor section of the Company's website at www.syndax.com, where a replay of the event will also be available for a limited time.
About Syndax Pharmaceuticals, Inc.
Syndax is a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies. Our lead product candidate, entinostat, which was granted Breakthrough Therapy designation by the FDA following positive results from our Phase 2b clinical trial, ENCORE 301, is currently being evaluated in a Phase 3 clinical trial for advanced hormone receptor positive, human epidermal growth factor receptor 2 negative breast cancer. Given its potential ability to block the function of immune suppressive cells in the tumor microenvironment, entinostat is also being evaluated in combination with approved PD-1 antagonists. Ongoing Phase 1b/2 clinical trials combine entinostat with KEYTRUDA® from Merck & Co., Inc. for non-small cell lung cancer and melanoma; with TECENTRIQ® from Genentech, Inc. for TNBC; and with BAVENCIOTM from Pfizer Inc. and Merck KGaA, Darmstadt, Germany, for ovarian cancer. Our second product candidate, SNDX-6352, is a monoclonal antibody that blocks the CSF-1 receptor and may also block the function of immune suppressive cells in the tumor microenvironment. SNDX-6352 is being evaluated in a single ascending dose Phase 1 clinical trial and is expected to be developed to treat a variety of cancers.
Investor Contact Heather Savelle Argot Partners [email protected] Tel 617.340.6072 Media Contact Eliza Schleifstein Argot Partners [email protected] Tel 973.361.1546
